What Can I Take Instead of Lisinopril?

Several drug classes can replace lisinopril, and the best choice depends on why you need to switch and what conditions you are treating. The most common swap is to an angiotensin receptor blocker (ARB) like losartan or valsartan, which works on the same blood-pressure pathway without the side effects that drive most people away from lisinopril. But calcium channel blockers, thiazide diuretics, and newer agents like sacubitril/valsartan or SGLT2 inhibitors are all legitimate alternatives in different situations. Your doctor will weigh the reason you’re stopping lisinopril against your other health conditions to pick the right replacement.

Why People Switch Off Lisinopril

Lisinopril belongs to the ACE inhibitor class, and the most notorious side effect of every ACE inhibitor is a persistent dry cough. It is not a mild throat-clearing; for many people it is a hacking, tickling cough that does not respond to cough medicine and can disrupt sleep. The underlying cause appears to be a buildup of bradykinin, a substance normally broken down by the ACE enzyme. When ACE is blocked, bradykinin accumulates and sensitizes the nerve endings in the airways, triggering the cough reflex.¹ Estimates vary, but roughly 5 to 20 percent of people on ACE inhibitors develop this cough, and it is more common in women and people of East Asian descent.

A less common but more dangerous reason to stop is angioedema, a sudden swelling of the lips, tongue, face, or throat that can obstruct the airway. In a large electronic health record study of nearly 135,000 patients on ACE inhibitors, about 0.7 percent developed angioedema over five years, with the highest risk concentrated in the first month after starting the drug.² ACE inhibitors are the leading cause of drug-induced angioedema in the United States, and the mechanism is the same bradykinin buildup that causes the cough.³ In rare cases, the swelling can affect the intestinal wall, mimicking a bowel obstruction. Anyone who has experienced ACE-inhibitor angioedema should not try a different ACE inhibitor; a different drug class is necessary.

Other reasons people stop lisinopril include elevated potassium levels, declining kidney function (sometimes paradoxically, since ACE inhibitors are also kidney-protective in many scenarios), dizziness from low blood pressure, or a planned pregnancy. Each of these situations points toward a different replacement.

ARBs as the Closest Swap

If your doctor is looking for a drug that works on the same hormonal pathway as lisinopril but avoids the cough, an ARB is the first place they will look. ARBs block the effects of angiotensin II at the receptor level rather than preventing its formation, which means bradykinin does not accumulate. That eliminates the cough for the vast majority of switchers and dramatically lowers the angioedema risk. Common ARBs include losartan, valsartan, candesartan, irbesartan, and olmesartan.

Because ARBs target the same renin-angiotensin system, they share most of lisinopril’s benefits: blood-pressure lowering, kidney protection in diabetic patients, and heart-failure management. Both ACE inhibitors and ARBs remain first-line agents for slowing the progression of diabetic kidney disease, and switching from one to the other preserves that protection.⁴ The practical downside is cost: ARBs tend to be slightly more expensive, though most are now available as generics and the gap has narrowed considerably. One cost-effectiveness analysis in heart failure estimated the average treatment cost at about $15,000 for ACE inhibitors versus $16,500 for ARBs over the analysis period, with ARBs producing only a marginal gain in quality-adjusted life years.⁵

One important caveat: if you had angioedema on lisinopril, ARBs are still considered an option by most guidelines, but there is a small residual risk (generally estimated under 2 percent) of cross-reactivity. Your doctor may have you take the first dose in a monitored setting and will discuss the risk with you. If you only had the cough, ARBs are a straightforward switch with very little concern.

Calcium Channel Blockers

Calcium channel blockers (CCBs) like amlodipine, nifedipine, and diltiazem lower blood pressure by relaxing the muscles in artery walls. They work through a completely different mechanism from ACE inhibitors, so there is zero risk of bradykinin-related cough or angioedema. Amlodipine is the most widely prescribed CCB and is available as a cheap generic.

CCBs are especially effective at preventing stroke. A large network meta-analysis found that dihydropyridine CCBs (the amlodipine/nifedipine subgroup) were associated with about a 39 percent reduction in stroke risk compared to placebo, the largest reduction of any single drug class studied.⁶ They are a particularly good choice if you have isolated systolic hypertension (the top number is high but the bottom number is normal), a pattern common in older adults.

Side effects are different from what you experienced on lisinopril. Ankle swelling is the most common complaint with amlodipine, and it can be cosmetically annoying even though it is medically benign. Some people also experience flushing, headaches, or heart palpitations when starting a CCB. Non-dihydropyridine CCBs like diltiazem and verapamil slow the heart rate, so they are used less often as a straightforward lisinopril replacement and more often when someone also has a fast heart rate or certain arrhythmias.

Thiazide and Thiazide-Like Diuretics

Hydrochlorothiazide and chlorthalidone are the classic first-line blood pressure drugs, and they remain effective alternatives to lisinopril. A trial in people with obesity and high blood pressure found that both lisinopril and hydrochlorothiazide lowered blood pressure significantly compared to placebo, though a larger percentage of lisinopril-treated patients reached the target diastolic pressure of under 90 mmHg (60 percent versus 43 percent).⁷ Longer-term data from a separate 52-week comparison also suggested lisinopril controlled blood pressure in a greater proportion of patients than hydrochlorothiazide alone, though combining the two was more effective than either.⁸

That said, thiazides have a long track record for reducing cardiovascular events, and many large trials used them as the reference standard for other drugs. In the network meta-analysis mentioned earlier, diuretics achieved about a 37 percent reduction in stroke and a 22 percent reduction in cardiovascular death compared to placebo, figures comparable to or slightly better than ACE inhibitors on those endpoints.⁶ Chlorthalidone in particular has a strong evidence base and is often preferred over hydrochlorothiazide by hypertension specialists.

The main drawbacks are metabolic. Thiazides can raise blood sugar and lower potassium. In the obesity trial above, patients on hydrochlorothiazide saw a significant increase in plasma glucose compared to those on lisinopril.⁷ If you have diabetes or prediabetes, your doctor will weigh these metabolic effects carefully. You will also need periodic blood tests to monitor potassium and kidney function, just as you likely did on lisinopril.

How the Major Classes Compare on Hard Outcomes

A question you might reasonably ask is whether switching off lisinopril means trading cardiovascular protection for comfort. The reassuring answer is that the four main first-line drug classes, namely ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics, all reduce the risk of heart attacks, strokes, and cardiovascular death by broadly similar amounts. A systematic review and network meta-analysis pooling data from large trials found that ACE inhibitors, dihydropyridine CCBs, and diuretics each reduced overall cardiovascular events by roughly 27 to 29 percent compared to placebo, with ARBs close behind at about 21 percent.⁶

A separate analysis comparing first-line drug classes directly (head to head rather than against placebo) found that when starting treatment with a single drug, ACE inhibitors/ARBs, CCBs, and thiazides were associated with similar risks of heart attack, stroke, and heart failure, while beta-blockers were associated with higher risk.⁹ The practical takeaway is that you are not stepping down to an inferior drug by moving from lisinopril to amlodipine or chlorthalidone. You are shifting to a different side-effect profile while maintaining strong cardiovascular protection.

Special Situations That Change the Calculus

Straightforward high blood pressure is one thing, but lisinopril is prescribed for several conditions beyond hypertension, and the replacement drug needs to match the reason it was prescribed in the first place.

Heart Failure With Reduced Ejection Fraction

If you are taking lisinopril for heart failure, the preferred replacement in many cases is not a plain ARB but sacubitril/valsartan (brand name Entresto). This combination drug pairs the ARB valsartan with sacubitril, which blocks an enzyme that degrades protective hormones in the heart. A systematic review and meta-analysis of 14 randomized trials covering more than 25,000 patients found that sacubitril/valsartan reduced all-cause mortality by about 12 percent compared to ACE inhibitors or ARBs alone in patients whose heart was pumping weakly (ejection fraction 40 percent or below).¹⁰ Hospitalizations for heart failure also dropped regardless of how strongly the heart was pumping. Current heart failure guidelines now favor sacubitril/valsartan over ACE inhibitors when it is tolerated and affordable.

If sacubitril/valsartan is not an option due to cost or side effects, a standard ARB like valsartan or candesartan is the next step. Heart failure patients should never be left without some form of renin-angiotensin system blockade unless there is a specific contraindication.

Diabetic Kidney Disease

Lisinopril is commonly used to slow the progression of diabetic kidney disease by reducing the pressure inside the kidney’s filtering units and lowering protein spilling into the urine. If you need to stop lisinopril, an ARB preserves this protection because it acts on the same system. SGLT2 inhibitors like empagliflozin and dapagliflozin have emerged as an important addition here. These drugs were originally designed to lower blood sugar by blocking glucose reabsorption in the kidneys, but trials have shown that they also lower blood pressure, reduce urinary protein, and slow the progression to end-stage kidney disease.¹¹ In practice, many patients with diabetic kidney disease now take an SGLT2 inhibitor in addition to an ARB. If you are switching off lisinopril, your doctor may put you on an ARB and add an SGLT2 inhibitor at the same time.

After a Heart Attack

ACE inhibitors are routinely started after a heart attack to protect the heart from remodeling, which is the process by which the damaged muscle stretches and weakens over time. An ARB is again the closest substitute if you cannot tolerate the ACE inhibitor. Beta-blockers are also part of standard post-heart-attack care, but they serve a different purpose (slowing the heart rate and reducing oxygen demand) and do not replace the specific role of renin-angiotensin blockade.

Beta-Blockers and Spironolactone

Beta-blockers like metoprolol, atenolol, and carvedilol were once standard first-line treatment for high blood pressure, but their reputation has slipped. The head-to-head evidence mentioned above found that beta-blockers as initial monotherapy were associated with higher risk of cardiovascular events compared to thiazides.⁹ Most guidelines now reserve beta-blockers for specific indications: heart failure, post-heart attack, certain arrhythmias, and high blood pressure that has not responded to other drugs. They are not the best one-for-one swap for lisinopril in someone who just has uncomplicated hypertension.

Spironolactone occupies a different niche. It is a mineralocorticoid receptor antagonist that works particularly well in resistant hypertension, meaning blood pressure that stays elevated despite three or more drugs. In one study, adding low-dose spironolactone to an existing regimen that already included ACE inhibitors, ARBs, and diuretics produced an additional average blood-pressure drop of about 25/12 mmHg at six months.¹² Spironolactone is not a typical lisinopril replacement on its own, but if you are switching off lisinopril and still struggling to reach your blood-pressure target on other drugs, it can be a powerful add-on. The main concerns are elevated potassium (which already needs monitoring on lisinopril, so your doctor will be watching for it) and hormonal side effects like breast tenderness in men.

Lifestyle Interventions as Part of the Transition

Switching medications is also a natural moment to revisit the non-drug side of blood pressure management. Exercise, weight loss, and dietary changes do not replace medications for most people, but they can lower the dose you need or sometimes eliminate the need for a drug entirely. A study testing the DASH diet (rich in fruits, vegetables, and low-fat dairy) combined with a weight-management program found that the proportion of participants who still met guideline criteria for needing a blood pressure drug dropped from roughly half to under a fifth, compared with essentially no change in the group receiving usual care.¹³

Reducing sodium intake, increasing potassium-rich foods, limiting alcohol, and getting regular aerobic exercise all have solid evidence behind them. If your blood pressure is only mildly elevated and you are stopping lisinopril due to side effects, these changes might be enough for your doctor to delay starting a new drug, at least temporarily, while monitoring your numbers closely.

Pregnancy and Planning for It

Lisinopril is strictly contraindicated in pregnancy. ACE inhibitors can cause serious birth defects and kidney damage in a developing fetus, especially in the second and third trimesters. If you are pregnant or planning to become pregnant, you need to switch before conception if possible.

The safer alternatives during pregnancy are limited. Methyldopa and labetalol (a combined alpha- and beta-blocker) have the longest safety records in pregnant women and remain the most widely recommended options. Nifedipine, a calcium channel blocker, is also commonly used, particularly for more urgent blood-pressure control later in pregnancy. ARBs are off limits for the same reason as ACE inhibitors: they act on the same hormonal system and carry similar fetal risks. Diuretics are generally avoided because they reduce blood volume, which is already precarious in pregnancy.

How Genetics and Ethnicity Influence the Choice

Blood pressure drugs do not work equally well in all populations, and this matters when choosing a lisinopril replacement. ACE inhibitors and ARBs tend to produce smaller blood-pressure drops in Black patients compared to white or Asian patients when used as monotherapy. This is thought to be related to lower levels of renin activity. As a result, guidelines often recommend that Black patients start with a CCB or thiazide diuretic rather than an ACE inhibitor or ARB, unless there is a compelling reason like diabetic kidney disease or heart failure.

Beyond broad population trends, there is growing interest in how individual genetic variation shapes drug response. Research on the ACE gene has shown that people with different versions of this gene vary in how much their diastolic blood pressure drops on an ACE inhibitor, with the response inversely correlated to plasma ACE activity.¹⁴ This kind of pharmacogenomic testing is not yet routine, but it may become part of clinical decision-making in the future. For now, the practical effect is that your doctor may try one or two alternatives before finding the one that works best for you, and that is a normal part of blood pressure management rather than a sign that something has gone wrong.

The Transition Itself

How you switch depends on the urgency. If you had angioedema, your doctor will stop lisinopril immediately and start a different class the same day, often a CCB since there is no cross-reactivity at all. If the issue is cough, you might taper or simply stop lisinopril and start an ARB. The cough usually resolves within one to four weeks after stopping, though for some people it lingers longer.

When switching between drug classes, doctors often overlap the old and new drugs briefly or monitor you within a few weeks to make sure the new drug is controlling your blood pressure adequately. If the new medication is in a completely different class, the dose will be calibrated independently rather than converted from your lisinopril dose, because there is no direct equivalency between, say, 20 mg of lisinopril and any particular dose of amlodipine.

One thing to avoid is stopping lisinopril without a plan. ACE inhibitors do not cause the same kind of abrupt rebound hypertension that some other drugs (like clonidine) can produce, but going without blood-pressure treatment for weeks while you decide what to take next is not harmless. If you are having side effects, call your doctor to arrange the switch rather than simply stopping on your own and waiting for your next appointment.

An Accidental Discovery Worth Knowing

Lisinopril and all other ACE inhibitors trace their origin to an unlikely source: snake venom. The first ACE inhibitor ever marketed, captopril, was synthesized based on the structure of a peptide discovered in the venom of the Brazilian pit viper Bothrops jararaca.¹⁵ Researchers in the 1970s noticed that the venom caused a dramatic drop in blood pressure and traced the effect to peptides that blocked ACE. Lisinopril was a later refinement of that original design. The reason this matters beyond cocktail-party trivia is that researchers continue to screen animal venoms for new cardiovascular compounds, and the next generation of blood pressure drugs may come from similarly unexpected sources. For now, though, the replacements already on the shelf cover the vast majority of situations where lisinopril needs to go.

1
PubMed. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough
2
PubMed Central. Epidemiology and Incidence of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record
3
PubMed Central. ACE inhibitor-induced bradykinin-mediated angioedema presenting as small bowel obstruction and life-threatening airway angioedema: a rare dual presentation
4
PubMed Central. Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
5
PubMed Central. Cost-effectiveness of ace inhibitors versus ARBs in heart failure management
6
JAMA Network Open. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis
7
PubMed. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial
8
PubMed. A 52-week comparison of lisinopril, hydrochlorothiazide, and their combination in hypertension
9
The American Journal of Medicine. Comparative Analysis of First-Line Antihypertensive Treatment Classes
10
PubMed Central. Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials
11
Diabetic Nephropathy. Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease
12
PubMed. Efficacy of low-dose spironolactone in subjects with resistant hypertension
13
PubMed Central. Lifestyle Interventions Reduce the Need for Guideline-Directed Antihypertensive Medication
14
Oxford Academic (American Journal of Hypertension). Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype
15
PubMed Central. Rapid screening and identification of ACE inhibitors in snake venoms using at-line nanofractionation LC-MS